This Phase 2b study is designed to evaluate the safety and efficacy of KT-621 in participants with uncontrolled moderate to severe eosinophilic asthma. The ma…

Eosinophilic Asthma

~Estimated

~$10 – $8,750

Kymera Therapeutics, Inc.NCT07323654

Phase 4

Fasenra Demonstrates Durability Over the Full 8-week Treatment Period

The goal of this observational study is to learn more about the effectiveness of benralizumab (Fasenra, 30 mg every 8 weeks) in maintaining asthma control in p…

Eosinophilic AsthmaSevere AsthmaSevere Eosinophilic Asthma+1 more

~Estimated

~$10 – $7,500

Endeavor HealthNCT07654842

Phase 3

BRISOTE: A Multicentre, Randomised, Double-Blind, Parallel Group, Active-Controlled, Phase 3b Study to Evaluate the Efficacy and Safety of Benralizumab 30 mg SC in Eosinophilic Asthma Patients Uncontrolled on Medium-Dose Inhaled Corticosteroid Plus Long-acting β2-Agonist.

This study evaluates the efficacy and safety of benralizumab as an add-on therapy in uncontrolled eosinophilic asthma participants treated with medium-dose ICS…

Eosinophilic Asthma

~Estimated

~$10 – $7,500

AstraZenecaNCT06750289